TRAZODONE, A NEW ANTI-DEPRESSANT - EFFICACY AND SAFETY IN ENDOGENOUS-DEPRESSION

  • 1 January 1979
    • journal article
    • research article
    • Vol. 40  (9) , 390-395
Abstract
The effectiveness of trazodone was assessed over 4 wk under double-blind conditions. Inpatients (28) with a diagnosis of endogenous depression received either trazodone, imipramine or placebo. Trazodone was significantly better than placebo and frequently better than imipramine according to analyses of the results of the Hamilton Psychiatric Scale for Depression, severity of illness and clinical global improvement ratings, and the Global Ward Behavior Scale. Significant improvement was evident in the trazodone group by the end of the 1st wk of therapy, particularly in those symptoms associated with depression and accompanying anxiety. There were fewer side effects with trazodone than with imipramine.

This publication has 0 references indexed in Scilit: